Harbin Pharmaceutical Group Co Ltd
SSE:600664
Harbin Pharmaceutical Group Co Ltd
SSE:600664
Price:
3.52
CNY
-2.22%
Market Closed
Market Cap:
¥8.9B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Harbin Pharmaceutical Group Co Ltd
SSE:600664
|
CN |
|
Jiang Zhong Pharmaceutical Co Ltd
SSE:600750
|
CN |
|
Jyothy Labs Ltd
BSE:532926
|
IN |
|
Mahamaya Steel Industries Ltd
NSE:MAHASTEEL
|
IN |
|
V
|
VMware Inc
XETRA:BZF1
|
US |
|
China Nonferrous Mining Corp Ltd
HKEX:1258
|
CN |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
E
|
Engcon AB
STO:ENGCON B
|
SE |
|
Donaldson Company Inc
NYSE:DCI
|
US |
|
H
|
Hansol Paper Co Ltd
KRX:213500
|
KR |
|
A
|
Adecoagro SA
F:ACD
|
LU |
Multiples-Based Value
The Multiples-Based Value of one
Harbin Pharmaceutical Group Co Ltd
stock under the Base Case scenario is
hidden
CNY.
Compared to the current market price of 3.52 CNY,
Harbin Pharmaceutical Group Co Ltd
is
hidden
.
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
Harbin Pharmaceutical Group Co Ltd Multiples-Based Value
LOCKED
Multiples Across Competitors
Competitors Multiples
Harbin Pharmaceutical Group Co Ltd Competitors
Harbin Pharmaceutical Group Co Ltd Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| CN |
|
Harbin Pharmaceutical Group Co Ltd
SSE:600664
|
8.9B CNY | 0.6 | 19.7 | 10.5 | 10.5 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
875.9B USD | 13.4 | 42.4 | 28.6 | 30.6 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
580.2B USD | 6.1 | 21.4 | 14.9 | 18.3 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 4.1 | 19.7 | 11.6 | 13.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
232B GBP | 5.2 | 30 | 16.6 | 23.4 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
299.1B USD | 4.5 | 16.1 | 10 | 12.2 | |
| CH |
|
Novartis AG
SIX:NOVN
|
236.4B CHF | 5.1 | 20.7 | 12.8 | 16.5 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 105.4 | -83.6 | 386.8 | 970 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 3.4 | 10.2 | 7.6 | 8.9 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
158.2B USD | 2.5 | 19.9 | 7.7 | 10.2 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
119.4B USD | 2.4 | 16.5 | 7 | 8.6 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
